Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib, Emerging Portfolio of Selective and Potent Targeted Therapeutics

Author: Benzinga Newsdesk | January 09, 2024 09:03am

Plan to initiate global, registration-directed SUMMIT Part 2 study of bezuclastinib in NonAdvSM patients during 1H 2024; present results from complete SUMMIT Part 1 at 2024 AAAAI annual conference in Q1 2024
On track to complete enrollment in global, pivotal Phase 3 PEAK study of bezuclastinib + sunitinib in 2nd-line GIST patients by end of 2024
On track to complete enrollment in registration-directed Phase 2 APEX study of bezuclastinib in AdvSM patients by end of 2024
Plan to initiate Phase 1 trial of CGT4859, a potential best-in-class, potent, selective and reversible FGFR2 inhibitor in 2H 2024

Posted In: COGT